ReShape Lifesciences Inc.
RSLS
$0.6355
$0.00050.08%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 16.64% | 1.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.64% | 1.08% | |||
| Cost of Revenue | 2.65% | 6.68% | |||
| Gross Profit | 26.90% | -2.66% | |||
| SG&A Expenses | 0.43% | -3.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.85% | -3.25% | |||
| Operating Income | 14.26% | 7.06% | |||
| Income Before Tax | 0.32% | 27.49% | |||
| Income Tax Expenses | -60.00% | 7.14% | |||
| Earnings from Continuing Operations | 0.88% | 27.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.88% | 27.27% | |||
| EBIT | 14.26% | 7.06% | |||
| EBITDA | 14.26% | 7.08% | |||
| EPS Basic | 15.29% | 32.36% | |||
| Normalized Basic EPS | 33.00% | 14.25% | |||
| EPS Diluted | 15.29% | 32.36% | |||
| Normalized Diluted EPS | 33.00% | 14.25% | |||
| Average Basic Shares Outstanding | 17.02% | 7.54% | |||
| Average Diluted Shares Outstanding | 17.02% | 7.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
